Gracell Updated Data on Deep and Durable Responses in Newly Diagnosed Multiple Myeloma

 

• Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months
• GC012F is a FasTCAR-enabled B-cell maturation antigen (BCMA) and CD19 dual-targeting autologous CAR-T therapy being evaluated for hematologic malignancies and autoimmune disease

https://www.biospace.com/article/releases/gracell-biotechnologies-presents-updated-clinical-data-from-fastcar-t-gc012f-demonstrating-deep-and-durable-responses-in-newly-diagnosed-multiple-myeloma-at-ash-2023/